BLOOMINGTON, Ind. – While the 2022 Inflation Reduction Act has had immediate impact on the delivery of health care, in coming years it will indirectly impact patients, providers, and companies in the life sciences industry.
Just this week, the Biden administration announced the 10 prescription drugs that have been selected for Medicare price negotiations. Other changes will come through changing incentives for market participants. Helping Hoosiers to cut through some of the clutter and understand the law’s impact is a Feb. 16 conference presented by the Indiana University Kelley School of Business.
The conference, “Industry Impact of the Inflation Reduction Act,” will take place on Friday, Feb. 16 at Ice Miller LLP, One Indiana Square, in Indianapolis. It is part of the Indiana Life Sciences Collaboration Series, presented by the Kelley School’s Center for the Business of Life Sciences.
George Telthorst
“Several sections of the 2022 Inflation Reduction Act involved healthcare,” said George Telthorst, the center’s director. “Among these are Medicare drug price negotiations, changes to Medicare Parts B and D, and continued ACA marketplace subsidies. Organizations are analyzing the effects on their operations and updating their strategic plans to respond accordingly.
“We are looking forward to hearing from various stakeholders from across the industry who will share their perspectives on the law’s current and future effects on healthcare plans, product portfolios and patient choices and costs.”
Presenters will include Scott Lain, a healthcare consultant in the Indianapolis office of Milliman, who at 9:15 a.m. will present the conference’s opening keynote, “Fundamentals of the Inflation Reduction Act’s Impact on Medicare.”
Other presenters will include Scott Ford, Healthcare Tax Practice leader and partner at Crowe LLP; Diane Hilligoss, associate vice president and assistant general counsel, value and access at Eli Lilly; Lisa Joldersma, founder and president of Birch Point Strategies; and Barrett Tenbarge, general counsel for Ranking Member and U.S. Sen Bill Cassidy (R-La.).
Led by David Shenberger, vice president of strategic development at CAI, they will discuss macro perspectives of the law.
A luncheon keynote featuring a panel of legal experts from Ice Miller will focus on legal challenges to the bill.
In the afternoon, a panel led by Bill Nihill, director of U.S. market access pipeline strategy at AbbVie, will discuss the law impact on industry segments. Panelists will be Alex Wolfe, director of government strategy and analytics at Eli Lilly; Abigail Lore, director of innovation policy at Pharmaceutical Research and Manufacturers of America (PhRMA); and Brian Tabor, president of the Indiana Hospital Association.
The Center for the Business of Life Sciences brings together key players from industry, academia, government, and economic development communities to share ideas and expertise. It drives the Kelley School’s life sciences agenda and provides connections to its outreach and research activity and its academic programs.
This is the second event in the 2023-24 conference series. The final event, “Tech: Don’t Be Afraid of Healthcare,” will take place on April 19 at the Indiana Biosciences Research Institute in 16 Tech Innovation District in Indianapolis.
The registration fee is $175 for each individual conference and lunch is included. Registration can be done online or by contacting Kelli Conder at the Kelley School at 812-856-0915 or kconder@indiana.edu. Full-time students an at accredited Indiana institution of higher learning may qualify for a student discount. Contact Conder for more information.
Series sponsors are Commissioning Agents, Inc., Elevance Health, Lilly, LabCorp and Reckitt Benckiser. Primary sponsors are AbbVie, Catalent, Crowe LLP and Ice Miller LLP. Supporting sponsors are BioCrossroads, Blueprint Marketing, and Miles Printing. Marketing sponsors are the Bloomington Economic Development Corporation, Indiana Health Information Exchange, IU Office of University Relations, and Linking Pharma Women.